16Aug 2023
A Promising siRNA-Based Therapy for Sustained LDL Cholesterol Reduction in High-Risk Patients

A Promising siRNA-Based Therapy for Sustained LDL Cholesterol Reduction in High-Risk Patients

The ORION-3 study explored the efficacy and safety of inclisiran, an injectable therapy targeting PCSK9, in lowering LDL cholesterol levels. Over four years, the study showed sustained LDL reductions by around 44%, with minimal adverse events. Inclisiran's twice-yearly dosing proved feasible and convenient, making it a promising option to manage high LDL cholesterol in high-risk patients, complementing oral medications.

  • #cardiology

Like

Save

Share